Immuron reports Q3 sales of Travelan up 13% vs. Q2

Immuron Limited announced continued strong sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Flavio Palumbo, Chief Commercial Officer, said, “As anticipated, we are achieving strong growth in North America with continued growth in Australia. We have secured core ranging in another nine pharmacy banner groups in Australia. We had our strongest monthly sales on amazon.com in the US. We now have distribution in ten pharmacy/grocery retailers in Canada.” Global sales of Travelan for the September 2024 quarter were AUD$1.5M, up 13% on prior quarter; for Australia, Travelan sales increased 3% to AUD$1.007M during the September 2024 quarter vs. AUD$0.983M for the June 2024 quarter. In North America, Travelan sales increased 48% to AUD$0.456M in the September 2024 quarter vs. AUD$0.309M in the June 2024 quarter.